$Agenus (AGEN.US)$
Agenus' BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Study Presented in an Oral Session at AACR
Monday, 28th April at 3:30 pm
Initial results from NEOASIS demonstrate BOT/BAL efficacy in the neoadjuvant setting across multiple MSS and MSI-H solid tumors
Agenus Inc. (NASDAQ: AGEN), a leader in immuno-oncology, today announced that data from the investigator sponsored NEOASIS study were presented in an oral session at the American Association for Cancer Research (AACR...

$Agenus (AGEN.US)$
Agenus' BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025
Friday, 25th April at 1:05 pm
Durable responses observed in heavily pretreated HCC patients who progressed on approved immunotherapies
Agenus Inc. (NASDAQ: AGEN), a clinical-stage immuno-oncology company, today announced updated data from the hepatocellular carcinoma (HCC) cohort of its ongoing Phase 1 study evaluating botensilimab (BOT) in combination with balstilimab (BAL). These findings are being pre...

$Agenus (AGEN.US)$ yup tapped 3.03

$Agenus (AGEN.US)$ Dead?

$Agenus (AGEN.US)$
Can Agenus' Cancer Therapy Breakthrough Transform "Cold Tumor" Treatment?

$Agenus (AGEN.US)$
Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications
Wednesday, 26th February at 4:48 pm
Agenus Inc. (NASDAQ: AGEN), a leader in immuno-oncology innovation, today highlights key scientific contributions in 2024-2025 that are shaping the future of cancer immunotherapy.
Agenus is advancing a robust clinical pipeline targeting complementary mechanisms to fight cancer, including checkpoint inhibitors, immune a...

$Agenus (AGEN.US)$
Can This Novel Triple Immunotherapy Crack the Code for Treatment-Resistant Gastric Cancer?

$Agenus (AGEN.US)$
Clinical Data Alert: Agenus Unveils Dual Cancer Treatment Results for Breakthrough BOT/BAL Therapy

$Incyte (INCY.US)$ $Agenus (AGEN.US)$ Reuters· 2 mins ago
Agenus Inc - Incyte to Terminate Agreement With Agenus Effective February 2026